Opinion: Biotech Buyout Ideas To Watch 2018
At 6AM, September 20, 2016. Stock halted. Pending news. My heartbeat was beating 110/bpm, high blood pressure rising, my mind thinking of all the worse case scenarios for the biotech I'm holding, is there a bad clinical trial study? patient died?, FDA halt clinical trial? CEO leaving? their building headquarter on fire or what? (maybe, I exaggerated this one). After 30 mins , then I read the headline "Allergan to Buy Tobira Therapeutics for $1.7 Billions." At the time, Tobira #TBRA was trading at $4.74 of yesterday closing price. Allergan said it would pay as much as $49.84 per share in contingent value right. It was one of the happiest day of my trading and investing life. We nailed the biggest premium in biotech buyout history, this is to credit my trading partner and co-founder of this site, Kristin, for her due diligence and hard work picked.
Moving forward to 2017, these are the notable buyout:
Feb 13, 2017 Allergan plc (AGN:NYSE) acquired ZELTIQ for $2.47 Billion
Feb 14, 2017 Hologic Inc (HOLX:NASDAQ) acquired Cynosure (CYNO:NASDAQ) for $1.4 Billion
August 7, 2017, German dialysis giant Fresenius is paying $2 Billion or $30 a share for NxStage (NXTM:NASDAQ)
August 28, 2017 Gilead Sciences Inc (GILD:NASDAQ) buy Kite Pharma for about $11 Billion in cash.
For the upcoming 2018 year, we think there will be more buyout from the biotech sector due to tax cut plan. These stocks are for opinion only and you should do your own research.
- Alnylam Pharmaceuticals Inc (ALNY:NASDAQ)
Dec 15, announces lift of FDA clinical hold on Fitusiran. http://investors.alnylam.com/news-releases/news-release-details/fda-lifts-clinical-hold-fitusiran
Follow with upgraded to Conviction Buy at Goldman Sachs. See the full list from our site https://www.tradersfish.com/Analyst
2. Clovis Oncology (CLVS:NASDAQ)
CLOVIS ONCOLOGY’S RUCAPARIB SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL IN ALL OVARIAN CANCER PATIENT POPULATIONS STUDIED IN PHASE 3 ARIEL3 MAINTENANCE TREATMENT TRIAL http://phx.corporate-ir.net/phoenix.zhtml?c=247187&p=irol-newsArticle&ID=2281511
3. Galapagos NV (GLPG:NASDAQ)
August, 09, 2017. GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial http://www.glpg.com/press-releases
4. Puma Biotechnology Inc (PBYI:NASDAQ)
July 17, 2017 U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer http://investor.pumabiotechnology.com/press-release/us-food-and-drug-administration-approves-pumas-nerlynx-neratinib-extended-adjuvant-tre
5. Portola Pharmaceuticals (PTLA:NASDAQ)
Dec 19, 2017 FDA approves Prior Approval Supplement (PAS) for Bevyxxa. http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=2323396
6. Vertex Pharmaceuticals Inc (VRTX:NASDAQ)
Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min) http://investors.vrtx.com/releasedetail.cfm?ReleaseID=1033559
Follow us on Twitter: Site handle @TradersFish, my is @BiotechMoney18 and for Kristin @Kris_tin27